Michele Porzio

Real-Life Safety and Effectiveness of Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis

Pierre‐Régis Burgel, À. Munck, I. Durieu et al. · American Journal of Respiratory and Critical Care Medicine · 2019 · 132 citations

Pharmacy, Pharmacology, Pharmacotherapy +15

Theratyping cystic fibrosis patients to guide elexacaftor/tezacaftor/ivacaftor out-of-label prescription

Elise Dréano, Pierre‐Régis Burgel, Aurélie Hatton et al. · European Respiratory Journal · 2023 · 87 citations

Medicine, Pharmacology, Pharmacotherapy +14

The French Compassionate Program of elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis with advanced lung disease and no F508del<i>CFTR</i>variant

Pierre‐Régis Burgel, Isabelle Sermet‐Gaudelus, I. Durieu et al. · European Respiratory Journal · 2023 · 85 citations

Medicine, Pharmacology, Pharmacotherapy +14

The expanded French compassionate programme for elexacaftor–tezacaftor–ivacaftor use in people with cystic fibrosis without a F508del CFTR variant: a real-world study

Pierre‐Régis Burgel, Isabelle Sermet‐Gaudelus, Emmanuelle Girodon et al. · The Lancet Respiratory Medicine · 2024 · 47 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +12

Clinical response to lumacaftor-ivacaftor in patients with cystic fibrosis according to baseline lung function

Pierre‐Régis Burgel, I. Durieu, R. Chiron et al. · Journal of Cystic Fibrosis · 2020 · 33 citations · Full text

Pharmacy, Clinical Sciences, Pharmacotherapy +14